Modality
Multispecific
MOA
GLP-1/GIP
Target
PCSK9
Pathway
Sphingolipid
CLLDLBCLET
Development Pipeline
Preclinical
Oct 2024
→ May 2025
PreclinicalCurrent
NCT08236617
272 pts·DLBCL
2024-10→2025-05·Recruiting
272 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2010mo agoInterim· DLBCL
Trial Timeline
Q42025Q2
Preclinical
Recruit…
Catalysts
Interim
2025-05-20 · 10mo ago
DLBCL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08236617 | Preclinical | DLBCL | Recruiting | 272 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |